1
|
Bardelli F, Giacobbe C, Ballirano P, Borelli V, Di Benedetto F, Montegrossi G, Bellis D, Pacella A. Closing the knowledge gap on the composition of the asbestos bodies. Environ Geochem Health 2023; 45:5039-5051. [PMID: 37058192 PMCID: PMC10310571 DOI: 10.1007/s10653-023-01557-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Accepted: 03/28/2023] [Indexed: 06/19/2023]
Abstract
Asbestos bodies (AB) form in the lungs as a result of a biomineralization process initiated by the alveolar macrophages in the attempt to remove asbestos. During this process, organic and inorganic material deposit on the foreign fibers forming a Fe-rich coating. The AB start to form in months, thus quickly becoming the actual interface between asbestos and the lung tissue. Therefore, revealing their composition, and, in particular, the chemical form of Fe, which is the major component of the AB, is essential to assess their possible role in the pathogenesis of asbestos-related diseases. In this work we report the result of the first x-ray diffraction measurements performed on single AB embedded in the lung tissue samples of former asbestos plant workers. The combination with x-ray absorption spectroscopy data allowed to unambiguously reveal that Fe is present in the AB in the form of two Fe-oxy(hydroxides): ferrihydrite and goethite. The presence of goethite, which can be explained in terms of the transformation of ferrihydrite (a metastable phase) due to the acidic conditions induced by the alveolar macrophages in their attempt to phagocytose the fibers, has toxicological implications that are discussed in the paper.
Collapse
Affiliation(s)
- F Bardelli
- National Research Council, Institute of Nanotechnology (CNR-Nanotec), Rome, Italy.
- Centre for the Study of Asbestos and Other Toxic Particulate, University of Torino, Turin, Italy.
| | - C Giacobbe
- Xenocs SAS, Grenoble, France
- European Synchrotron Radiation Facility, Grenoble, France
| | - P Ballirano
- Department of Earth Sciences, La Sapienza University, Rome, Italy
| | - V Borelli
- Department of Physiology and Pathology, University of Trieste, Trieste, Italy
| | - F Di Benedetto
- Department of Earth Sciences, University of Ferrara, Ferrara, Italy
| | - G Montegrossi
- National Research Council, Institute of Geoscience and Earth Resources (CNR-IGG), Florence, Italy
| | - D Bellis
- Centre for the Study of Asbestos and Other Toxic Particulate, University of Torino, Turin, Italy
| | - A Pacella
- Department of Earth Sciences, La Sapienza University, Rome, Italy
| |
Collapse
|
2
|
Feige A, Bradaczek L, Michak M, Günther D, Grauer M, Mondal B, Giacobbe C, Bright E, Benndorf C, Tonner-Zech R, Oeckler O. The crystal chemistry of binary beryllium dipnictides – new binary structure types between Zintl polyanions and Grimm Sommerfeld compounds. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322094475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
3
|
Bradaczek L, Feige A, Michak M, Günther D, Benndorf C, Giacobbe C, Bright E, Paulmann C, Stöger B, Oeckler O. Ordered and disordered structural variety in supposedly simple beryllium arsenide and beryllium phosphide. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322091896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
4
|
Giacobbe C, Di Taranto M, Palma D, Gelzo M, Caputo M, Cardiero G, Corso G, Guardamagna O, Fortunato G. Identification of a rare variants in ABCG5/ABCG8 genes in patients with clinical suspect of familial hyperchoelsterolemia. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Di Taranto M, Giacobbe C, Buonaiuto A, Calcaterra I, Palma D, Maione G, Cardiero G, Iannuzzo G, Di Minno M, Rubba P, Fortunato G. Genetics and biochemical profile of patients with homozygous familial hypercholesterolemia. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Buonaiuto A, Gentile M, Calcaterra I, Giacobbe C, Tripaldella M, Forte F, Di Minno M, Iannuzzo G, Fortunato G, Rubba P. Correlation between different LDL-R mutations and response to AB-PCSK9 therapy in a group of patient with genetic diagnosis of familial hypercholesterolemia. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Calcaterra I, Di Minno A, Gentile M, Tripaldella M, Buonaiuto A, Forte F, Di Taranto M, Giacobbe C, Iannuzzo G, Rubba P, Di Minno M. Changes in markers of subclinical atherosclerosis in patients with familial hypercholesterolemia treated with evolocumab: a prospective cohort study. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
PCSK-9-i demonstrated efficacy in cholesterol reduction and prevention of cardiovascular events.
Purpose
Changes in lipid-profile, oxidative stress and subclinical atherosclerosis markers in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with PCSK-9-i.
Methods
Patients with FH starting a treatment with Evolocumab® were included. TC, LDL-C, Lp(a), small dense LDL (assessed byLDL score), 11-dehydro-thromboxane (11-TXB2), 8-iso-prostaglandin-2alpha (8-iso-PGF2α),FMD, RHI and carotid stiffness were evaluated at baseline and after 12weeks of treatment.
Results
25 subjects were enrolled (52% males, mean age 51.5 years). At the 12-week, the median reduction was 38% for TC, 52% for LDL-C, 7% for Lp(a) and 46% for LDL score; 11-TXB2 and 8-iso-PGF2α were reduced of 18% and 17%, respectively. FMD changed from4.78%±2.27 to10.6%±5.89 (p<0.001), with RHI changing from 2.37±1.23 to 3.76±1.36 (p<0.001). Carotid stiffness changed from 8.8 (IQR: 7.0–10.4)m/sec to 6.6 m/sec (IQR: 5.4–7.5), p<0.001). At a multivariate analysis, changes in LDL score predicted changes in FMD (β=−0.846, p=0.015) in carotid stiffness (β=0.429, p=0.041), and in 8-iso-PGF2α (β=0.778, p=0.012).
Conclusions
Small dense LDL reduction is related to changes in oxidative stress and in subclinical atherosclerosis markers in FH patients treated with Evolocumab®.
Changes in endothelial function
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - A Di Minno
- Federico II University Hospital, Naples, Italy
| | - M Gentile
- Federico II University Hospital, Naples, Italy
| | | | - A Buonaiuto
- Federico II University Hospital, Naples, Italy
| | - F Forte
- Federico II University Hospital, Naples, Italy
| | | | - C Giacobbe
- Federico II University Hospital, Naples, Italy
| | - G Iannuzzo
- Federico II University Hospital, Naples, Italy
| | - P.O.F Rubba
- Federico II University Hospital, Naples, Italy
| | | |
Collapse
|
8
|
Buonaiuto A, Gentile M, Calcaterra I, Giacobbe C, Tripaldella M, Forte F, Iannuzzo G, Di Minno M, Fortunato G, Rubba P. Correlation between different LDL-R mutations and response to ab-PCSK9 therapy in a group of patient with genetic diagnosis of Familial Hypercholesterolemia. Preliminary report. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3332] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant disease that leads to premature cardiovascular disease (CAD). The availability of ab-PCSK9 has changed the approach to therapy.
Purpose
To evaluate the relationship between different types of mutations in LDLR gene and response to ab-PCSK9.
Methods
73 FH patients, 33 women and 40 men (53.9±13. yrs), in primary prevention (N=46) and secondary prevention (N=27), were recruited. This sample included patients with mutations in LDLR gene: heterozygotes for missense mutations (N=31), for null mutations (N=31), compound heterozygotes or homozygotes (N=11). At baseline, the whole sample had a maximally tolerated lipid lowering therapy (MT-LLT) without ab-PCSK9; 16 patients had MT-LLTs intolerance. After 160 days with ab-PCSK9 therapy we evaluated the achievement of a goal (LDL-C<70 mg/dL in primary prevention without Diabetes Mellitus, LDL-C<55 mg/dL).
Results
After 160 days of therapy with ab-PCSK9 (45 patients on Alirocumab, 28 patients on Evolocumab) and MT-LLT, 29/73 patients (39.7%) of the whole sample achieve the goal of LDL-C. Of them 14/29 (48.2%) were in primary prevention, 15/29 (51.7%) in secondary prevention, no difference in achievement of the goal. We then evaluated the percent of patients achieving the goal of LDL-C:
15/31 (48.3%) patients with missense mutation and 14/31 (45.1%) patients with null mutation, no significant difference among groups;
0/11 compound heterozygotes or homozygotes;
3/16 (18.7%) MT-LLTs intolerance.
The other main cardiovascular risk factors did not influence of the achievement the goal of LDL cholesterol.
Conclusions
Lack of correlation between type of mutation in heterozygous FH patients and ab-PCSK9 therapy response; response was significantly poorest in patients with compound heterozygosis or homozygosis mutation as compared to heterozygotes; the intolerance to MT-LLT was significant in the achievement of the goal of LDL-C.
Different between guideline 2016 vs 2019
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- A Buonaiuto
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - M Gentile
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - I.L Calcaterra
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - C Giacobbe
- ASL Napoli 1 Centre, 2Dipartimento di Medicina molecolare e Biotecnologie mediche, Università “Federico II” di Napoli, Na, Napoli, Italy
| | - M Tripaldella
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - F Forte
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - G Iannuzzo
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - M.N.D Di Minno
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - G Fortunato
- ASL Napoli 1 Centre, 2Dipartimento di Medicina molecolare e Biotecnologie mediche, Università “Federico II” di Napoli, Na, Napoli, Italy
| | - P.O.F Rubba
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| |
Collapse
|
9
|
Guaraldi F, Di Taranto M, Giacobbe C, Fortunato G, Guardamagna O. Heterozygous familial hypercholesterolemia (HeFH) in children: an Italian experience. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Dutta B, Çakır A, Giacobbe C, Al-Zubi A, Hickel T, Acet M, Neugebauer J. Ab initio Prediction of Martensitic and Intermartensitic Phase Boundaries in Ni-Mn-Ga. Phys Rev Lett 2016; 116:025503. [PMID: 26824549 DOI: 10.1103/physrevlett.116.025503] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Indexed: 06/05/2023]
Abstract
Despite the importance of martensitic transformations of Ni-Mn-Ga Heusler alloys for their magnetocaloric and shape-memory properties, the martensitic part of their phase diagrams is not well determined. Using an ab initio approach that includes the interplay of lattice and vibrational degrees of freedom we identify an intermartensitic transformation between a modulated and a nonmodulated phase as a function of excess Ni and Mn content. Based on an evaluation of the theoretical findings and experimental x-ray diffraction data for Mn-rich alloys, we are able to predict the phase diagram for Ni-rich alloys. In contrast to other mechanisms discussed for various material systems in the literature, we herewith show that the intermartensitic transformation can be understood solely using thermodynamic concepts.
Collapse
Affiliation(s)
- B Dutta
- Max-Planck-Institut für Eisenforschung GmbH, D-40237 Düsseldorf, Germany
| | - A Çakır
- Muğla Üniversitesi, Metalurji ve Malzeme Mühendisliği Bölümü 48000 Muğla, Turkey
| | - C Giacobbe
- European Synchrotron Research Facility, 38043 Grenoble Cedex 9, France
| | - A Al-Zubi
- Max-Planck-Institut für Eisenforschung GmbH, D-40237 Düsseldorf, Germany
| | - T Hickel
- Max-Planck-Institut für Eisenforschung GmbH, D-40237 Düsseldorf, Germany
| | - M Acet
- Experimentalphysik, Universität Duisburg-Essen, D-47048 Duisburg, Germany
| | - J Neugebauer
- Max-Planck-Institut für Eisenforschung GmbH, D-40237 Düsseldorf, Germany
| |
Collapse
|